A detailed history of Bank Of America Corp transactions in Ocugen, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 641,071 shares of OCGN stock, worth $634,660. This represents 0.0% of its overall portfolio holdings.

Number of Shares
641,071
Previous 273,783 134.15%
Holding current value
$634,660
Previous $449,000 121.16%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.18 - $1.98 $433,399 - $727,230
367,288 Added 134.15%
641,071 $993,000
Q1 2024

May 15, 2024

BUY
$0.5 - $1.83 $59,301 - $217,041
118,602 Added 76.43%
273,783 $449,000
Q4 2023

Feb 14, 2024

SELL
$0.36 - $0.57 $77,923 - $123,378
-216,454 Reduced 58.24%
155,181 $88,000
Q2 2023

Aug 14, 2023

SELL
$0.45 - $0.88 $53,274 - $104,181
-118,388 Reduced 24.16%
371,635 $200,000
Q1 2023

May 12, 2023

SELL
$0.82 - $1.33 $1.96 Million - $3.18 Million
-2,389,134 Reduced 82.98%
490,023 $416,000
Q4 2022

Feb 10, 2023

BUY
$1.11 - $1.87 $1.04 Million - $1.75 Million
933,507 Added 47.98%
2,879,157 $3.74 Million
Q3 2022

Nov 14, 2022

BUY
$1.75 - $3.1 $1.27 Million - $2.25 Million
726,986 Added 59.65%
1,945,650 $3.46 Million
Q2 2022

Aug 12, 2022

SELL
$1.83 - $3.45 $2.88 Million - $5.42 Million
-1,571,175 Reduced 56.32%
1,218,664 $2.77 Million
Q1 2022

May 16, 2022

BUY
$2.34 - $4.72 $3.81 Million - $7.68 Million
1,626,604 Added 139.83%
2,789,839 $9.21 Million
Q4 2021

Feb 08, 2022

BUY
$4.38 - $15.67 $4.65 Million - $16.6 Million
1,062,051 Added 1049.62%
1,163,235 $5.29 Million
Q3 2021

Nov 15, 2021

SELL
$6.36 - $8.51 $2.09 Million - $2.79 Million
-328,377 Reduced 76.44%
101,184 $726,000
Q2 2021

Sep 13, 2021

BUY
$5.52 - $15.68 $2.37 Million - $6.74 Million
429,561 New
429,561 $3.45 Million

Others Institutions Holding OCGN

About Ocugen, Inc.


  • Ticker OCGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,566,000
  • Market Cap $214M
  • Description
  • Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...
More about OCGN
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.